Ipca Laboratories Ltd., incorporated in the year 1949, is a Mid Cap company (having a market cap of Rs 27807.25 Crore) operating in Pharmaceuticals sector.
Financials
For the quarter ended 30-06-2021, the company reported a Consolidated Total Income of Rs 1586.81 Crore, up 39.86 % from last quarter Total Income of Rs 1134.58 Crore and up 2.61 % from last year same quarter Total Income of Rs 1546.49 Crore. Company reported net profit after tax of Rs 309.10 Crore in latest quarter.
Investment Rationale
The brokerage remains positive on IPCA on the back of: a) enhanced marketing efforts driving sustainable industry beating growth in DF, b) backward integration and efficient manufacturing in the API segment and c) addition of products/new tender wins in the Institutional segment.
Promoter/FII Holdings
Promoters held 46.3 per cent stake in the company as of June 30, 2021, while FIIs held 17.8 per cent, DIIs 25.3 per cent and public & others 10.6 per cent.
(Disclaimer: Views and recommendations given in this section are the analysts’ own and do not represent those of ETMarkets.com. Please consult your financial adviser before taking any position in the stock/s mentioned.
